The company said Repatha global sales growth for the 3 months ended March 31, 2026 was driven by volume growth of 35% and favorable changes to estimated sales deductions of 8%, partially offset by lower net selling price of 7%.

10-QQuarterly reportFiled May 1, 2026Period of report Mar 31, 2026Summary published (UTC) Oct 4, 2026

Key points

AI summary

The company said Repatha global sales growth for the 3 months ended March 31, 2026 was driven by volume growth of 35% and favorable changes to estimated sales deductions of 8%, partially offset by lower net selling price of 7%.
The company cited unfavorable changes to estimated sales deductions of 18% and lower net selling price of 15% as the main factors behind the decline in ENBREL sales for Q1 2026. For Prolia, it said the decrease was driven by lower volume of 17%, lower net selling price of 10% and a 4% impact from lower inventory.
The company said that on April 27, 2026, CDER proposed to withdraw approval of TAVNEOS, and that on April 30, the FDA posted a related notice. The company said it continues to believe TAVNEOS demonstrates effectiveness and a favorable benefit-risk profile, and that TAVNEOS will remain on the market while the process is pending.
The company said it issued $4.0 billion of debt in Q1 2026, redeemed the €750 million 2.00% 2026 euro Notes ($833 million) and paid dividends of $1.4 billion. It said it did not repurchase any shares during the period.

Key figures

Quarter ended March 31, 2026

Revenue: $8.6B
Operating income: $2.7B
Net income: $1.8B
EPS: $3.34
Operating cash flow: $2.2B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Drivers of Repatha Sales Growth in Q1 2026

The company said Repatha global sales growth for the 3 months ended March 31, 2026 was driven by volume growth of 35% and favorable changes to estimated sales deductions of 8%, partially offset by lower net selling price of 7%.

Source · Based on the MD&A text of the filing

Drivers of ENBREL and Prolia Sales Declines

The company cited unfavorable changes to estimated sales deductions of 18% and lower net selling price of 15% as the main factors behind the decline in ENBREL sales for Q1 2026. For Prolia, it said the decrease was driven by lower volume of 17%, lower net selling price of 10% and a 4% impact from lower inventory.

Source · Based on the MD&A text of the filing

Proposed Withdrawal of TAVNEOS Approval

The company said that on April 27, 2026, CDER proposed to withdraw approval of TAVNEOS, and that on April 30, the FDA posted a related notice. The company said it continues to believe TAVNEOS demonstrates effectiveness and a favorable benefit-risk profile, and that TAVNEOS will remain on the market while the process is pending.

Source · Based on the MD&A text of the filing

Debt Issuance, Redemption and Dividends in Q1 2026

The company said it issued $4.0 billion of debt in Q1 2026, redeemed the €750 million 2.00% 2026 euro Notes ($833 million) and paid dividends of $1.4 billion. It said it did not repurchase any shares during the period.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.